Content area
Full Text
Preclinical research can play a big role in pursuing new combination therapies . Case in point: Infinity's ($INFI) duvelisib (IPI-145). Partnered with AbbVie ($ABBV), investigators have gone back to the lab to help establish what the PI3K-delta/gamma inhibitor might best be paired with. And not too surprisingly they concluded that AbbVie's BCL-2 protein inhibitor venetoclax (ABT-199) might make a good match.
Working with researchers at MD Anderson Cancer Center, a team of investigators evaluated gene and protein expression in samples of chronic lymphocytic...